Form 4: Stoke Therapeutics Director Acquires Shares via RSU Vesting

Stoke Therapeutics Director Arthur A. Levin acquired 1,211 shares of common stock through the vesting of Restricted Stock Units.

Summary

• Arthur A. Levin, a Director at Stoke Therapeutics, Inc. (STOK), acquired 1,211 shares of common stock.
• The acquisition occurred on December 31, 2025, through the exercise or conversion of derivative securities (Restricted Stock Units).
• Each Restricted Stock Unit represents a contingent right to receive one share of the issuer's Common Stock upon settlement.
• The RSUs vested as to 1/4 of the total award quarterly on the last day of March, June, September, and December, contingent on continued service.
• The transaction price for the acquired shares was $0, as is typical for RSU vesting.
• Following this transaction, Arthur A. Levin directly holds 4,842 shares of common stock and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust, totaling 22,821 shares.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a routine RSU vesting, it signifies a director's continued equity stake and alignment with shareholder interests. It's not a direct open market purchase, which would typically carry stronger positive sentiment, but it's not negative.

Positives

• A director acquiring shares, even through RSU vesting, generally indicates continued alignment of interests between management and shareholders.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the Restricted Stock Units.

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation, which is a common practice across all industries, including the biotechnology sector where Stoke Therapeutics operates. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• The acquisition of shares by Director Arthur A. Levin through RSU vesting is a related party transaction, as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The transaction indicates continued alignment of a director's interests with those of shareholders through equity ownership.

Next Steps

• Future quarterly vesting of remaining Restricted Stock Units will occur on the last day of March, June, September, and December, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled vesting of Restricted Stock Units for a director. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It merely confirms a director's ongoing equity stake, which is a minor positive for governance and alignment but not a catalyst for a 'buy' or 'sell' decision.

Keywords

Stoke Therapeutics, STOK, Arthur A. Levin, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Common Stock, Beneficial Ownership